Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
anle138b · 1 trial · 1 indication
PK parameter: Cmax for caffeine.
PK parameter: Cmax for midazolam.
Cmax for caffeine.
Cmax for midazolam
PK parameter: Cmax for caffeine.
PK parameter: Cmax for midazolam.
PK parameter: Cmax for TEV-56286.
PK parameter: Cmax for TEV-56286 (Part II).
| Arm | Type | Description |
|---|---|---|
| anle138b (TEV-56286) as perpetrator (part I) | EXPERIMENTAL | Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days) Victim drugs: Caffeine 200 mg Midazolam 2 mg |
| anle138b (TEV-56286) as victim (part II) | EXPERIMENTAL | Drug: fluvoxamine 100 mg QD for 5 days Victim drug: TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine |
| Name | Type | Description |
|---|---|---|
| anle138b (TEV-56286) | DRUG | Anle138b (TEV-56286) as perpetrator |
| Fluvoxamine 100 mg QD for 5 days | DRUG | Anle138b (TEV-56286) as victim |
Inclusion Criteria: * Healthy males or healthy females of non-childbearing potential * Must provide written informed consent for participation in the study and must be able to understand the study requirements * Body mass index (BMI) 18.5 to 32.0 kg/m2. * Must agree to adhere to the contraception r...
anle138b is an investigational small molecule being developed by Teva Pharmaceutical Industries Limited (TEVA). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other.
anle138b is being studied for use in healthy volunteers. It is an investigational small molecule in Phase 1 clinical development. The drug is not approved for any indication and is still in clinical trials.
anle138b is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting clinical trials to evaluate the drug in healthy volunteers.
anle138b is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers as part of early-stage clinical trials.
anle138b has one completed Phase 1 clinical trial, NCT05532358, titled "A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)". The trial enrolled 54 healthy volunteers in the United Kingdom.
Yes, anle138b is also known as TEV-56286. The clinical trial NCT05532358 refers to the drug as TEV-56286 (anle138b), confirming that both names refer to the same investigational small molecule.